Robert W. Duggan, Co-Chief Executive Officer and Director of Summit Therapeutics Inc. (NASDAQ:SMMT), filed a Form 4 on November 20, 2026, disclosing that his spouse exercised a stock option covering 300,000 shares of common stock at $1.06 per share on that same date.

Key Highlights

  • Option exercise: Duggan's spouse exercised an option to purchase 300,000 shares of Summit Therapeutics common stock at an exercise price of $1.06 per share on November 20, 2026.
  • Transaction code M: The filing records the transaction under code M, reflecting an exercise of a derivative security.
  • Remaining derivative position: Following the transaction, 500,000 stock options remain beneficially owned indirectly by Duggan through his spouse.
  • Indirect holdings after exercise: The spouse's direct beneficial ownership in common stock following the transaction is reported as 831,000 shares.
  • Direct ownership reported: Duggan's direct beneficial ownership of common stock is listed at 573,883,879 shares.
  • Beneficial ownership disclaimed: Duggan disclaims beneficial ownership of securities held indirectly, except to the extent of his pecuniary interest, according to the filing.

Spouse's Option Exercise and Duggan's Reported Holdings at Summit Therapeutics

According to the Form 4 filing, the transaction on November 20, 2026 involved the exercise of a stock option originally granted to Duggan's spouse on June 28, 2022. The filing states the option was subject to certain performance criteria at grant. Per the filing's explanation, on August 23, 2024, the option vested as to 260,000 shares following satisfaction of certain performance criteria. The filing further states that on April 29, 2025, the option was modified to require only service-based vesting conditions going forward, at which point an additional 520,000 shares vested, with the remaining 520,000 shares set to vest in three equal annual installments, the first of which occurred on October 13, 2025.

The 300,000 shares acquired in the November 20, 2026 exercise are held indirectly by Duggan through his spouse, with the filing recording an exercise price of $1.06 per share and a derivative security price of $0. Following the exercise, the filing shows the spouse holds 831,000 shares of common stock directly, and Duggan retains 500,000 unexercised options indirectly through his spouse, with an expiration date of June 28, 2032.

In addition to holdings tied to his spouse, the filing reports Duggan holds 573,883,879 shares of common stock directly. Additional indirect holdings are listed through the Mahkam Zanganeh Revocable Trust (25,824,474 shares), an immediate family member of the spouse (76,680 shares), and the Shaun Zanganeh Irrevocable Trust (10,199,776 shares). The filing notes that Duggan disclaims beneficial ownership of all indirectly reported securities except to the extent of his pecuniary interest.

What Was Disclosed

The filing reports a November 20, 2026 exercise of 300,000 stock options by the spouse of Co-CEO Robert W. Duggan at $1.06 per share, along with a snapshot of Duggan's total direct and indirect beneficial ownership in Summit Therapeutics common stock and remaining derivative securities.